Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 31 Advanced Solid Tumors 25 Advanced Solid Tumor 24 Carcinoma, Non-Small-Cell Lung 20 Neoplasms 15 Solid Tumor 12 Prostatic Neoplasms 12 Multiple Myeloma 12 Neoplasm Metastasis 11 Recurrence 10 Pancreatic Neoplasms 10 Small Cell Lung Carcinoma 9 Ovarian Neoplasms 9 Lung Neoplasms 9 Stomach Neoplasms 8 Melanoma 8 Lymphoma, Large B-Cell, Diffuse 8 Leukemia, Myeloid, Acute 8 Carcinoma, Hepatocellular 8 Triple Negative Breast Neoplasms 7 Sarcoma 7 Colorectal Neoplasms 7 Uterine Cervical Neoplasms 6 Solid Tumors 6 Carcinoma, Transitional Cell 5 Advanced Solid Tumour 5 Squamous Cell Carcinoma of Head and Neck 4 Nasopharyngeal Carcinoma 4 Myelodysplastic Syndromes 4 Lymphoma 4

Interventions

folfirinox 1 devimistat 1 Paclitaxel 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Injections 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pancreatic Cancer Metastatic × Injections × Clear all

NCT06752811 2026-02-10

pompom

Shanghai Yizhong Pharmaceutical Co., Ltd.

Phase 3 Recruiting

Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡